Patients with disseminated advanced cancer who undergo surgery are far more likely to endure long hospital stays and readmissions, referrals to extended care facilities and death, UC Davis researchers have found.
Their study, published today in PLOS One, highlights the dilemma physicians and surgeons face when their terminally ill cancer patients are diagnosed with conditions that may benefit from surgery, such as bowel obstruction, as well as the need for substantive discussions about the risks of surgery and implications on future quality of life.
“We commonly consult with patients who have acute surgical conditions and advanced cancer, and it has left us to weigh the risks and benefits of surgical intervention,” said lead author Sarah B. Bateni, who is completing a research residency with the UC Davis Department of Surgery. “It’s important to carefully examine their risks before proposing surgery, and to understand their goals for their remaining days.”
For the study, Bateni and colleagues examined the cases of approximately 18,000 patients who had stage 4 (metastatic) cancer and surgery. The cases were compared with patients who had similar characteristics such as age, gender and functional status before surgery and underwent similar operations but who did not have stage 4 cancer.
They found that the group of patients with stage 4 cancer spent more time in the hospital (32 percent vs. 20 percent), were readmitted to the hospital more frequently (16 percent vs. 10 percent), were more often referred to another facility such as skilled nursing (16 percent to 13 percent) and had higher mortality within 30 days of their procedures (8 percent vs. 2.5 percent) than their counterparts who did not have late-stage cancers.
What was most surprising, Bateni said, was that stage 4 cancer patients who didn’t have any complications during their hospitalization ended up staying in the hospital longer, were readmitted more often, were more often discharged to other facilities and had higher 30-day mortality compared to patients who didn’t have stage 4 cancer.
“Stage 4 cancer really is an indicator of the frailty of these patients and is itself a risk factor for readmission, prolonged stays in the hospital and discharge to other facilities,” she said.
Bateni and her co-authors concluded that doctors and surgeons need to talk with their terminally ill cancer patients about their end-of-life goals, palliative care and the risks and benefits of surgery.
“We all need to clarify the goals of care for patients with advanced cancer prior to providing – or even discussing – the potential surgical interventions,” she said.
Given that the prevailing wisdom has been that surgery is the only treatment option for these patients, the researchers now plan to analyze the outcomes of stage 4 cancer patients with conditions that are considered operable but who don’t have surgery.
The study is entitled “Increased Rates of Prolonged Length of Stay, Readmissions, and Discharge to Care Facilities among Postoperative Patients with Disseminated Malignancy: Implications for Clinical Practice.” Co-authors include Frederick J. Meyers, Richard J. Bold and Robert J. Canter, all of UC Davis.
UC Davis Comprehensive Cancer Center is the only National Cancer Institute-designated center serving the Central Valley and inland Northern California, a region of more than 6 million people. Its specialists provide compassionate, comprehensive care for more than 10,000 adults and children every year, and access to more than 150 clinical trials at any given time. Its innovative research program engages more than 280 scientists at UC Davis, Lawrence Livermore National Laboratory and Jackson Laboratory (JAX West), whose scientific partnerships advance discovery of new tools to diagnose and treat cancer. Through the Cancer Care Network, UC Davis collaborates with a number of hospitals and clinical centers throughout the Central Valley and Northern California regions to offer the latest cancer care. Its community-based outreach and education programs address disparities in cancer outcomes across diverse populations. For more information, visit cancer.ucdavis.edu.